Biochemicals & reagents
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977 2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235 3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517 4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981 5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446 6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58 7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int.J.Mol.Sci., 21 E2657
Favipiravir is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir (1,2,3). This compound displayed no cytotoxicity in a variety of cells and has been shown to selectively inhibit viral RNA-dependent RNA polymerase (4). It has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses (5). It is in clinical trials for the treatment of SARS-CoV-2 (6,7).